06/11/2025
I’m pleased to share our latest publication, the world’s first clinical trial on this novel FVR IOL, “Efficacy and Safety Evaluation of a New Full Visual Range versus Monofocal IOL in Cataract Patients: A Randomized, Controlled Canadian Clinical Trial,” published online ahead-of-print today in JCRS.
This multi-centre, double-masked clinical trial, conducted at nine sites across Canada, is an in-platform comparison of a novel, continuous full visual range (FVR) IOL with smoothed diffractive echelettes and a monofocal control (enVista Envy vs enVista monofocal).
🔍 Some Highlights from This Study:
✅ Non-inferior distance vision to the monofocal control
✅ Superior intermediate and near vision (p < 0.0001)
✅ Overall binocular defocus curve performance of 3.5D of continuous range at or above 0.2 logMAR, compared to ~2D with the monofocal
✅ No statistically significant difference in the percentage of patients reporting “None” or “A Little” bothersomeness to glare, halos, or starbursts at 6 months on a directed, validated, non-proprietary, Rasch-calibrated questionnaire (QoV)
✅ 91.8% of patients reporting spectacle independence for near vision tasks
🧠 Several novel IOL design features likely contributed to these findings:
• Smoothed-edge diffractive echelettes
• Distance-dominant design under mesopic conditions
• Novel apodization pattern
🌙 Will patients be able to read in dim lighting?
✅ 84.3% of patients reported “No” or “A little” difficulty “Seeing objects close to you in poor or dim lighting”
Thank you to my co-author Dr. Paul Harasymowycz, MD, our co-investigators at nine sites across Canada, and to the sponsor, Bausch + Lomb — particularly their engineering, research, and medical affairs teams.
📄 Read the article (Open Access): http://bit.ly/4l6UBUZ